Form 4: Daxor Corp Director Granted Stock Options

Daxor Corp director Caleb DesRosiers has been granted stock options contingent on SEC approval of an amended incentive plan.

Summary

• Caleb DesRosiers, a Director at Daxor Corp (DXR), was granted 2,500 stock options with an exercise price of $10.14.
• The grant is contingent upon the SEC's approval to amend the Daxor Corporation 2020 Incentive Compensation Plan.
• These options are set to vest in three installments: 833 on June 23, 2026, 833 on June 23, 2027, and 834 on June 23, 2028.
• The options have an expiration date of June 23, 2031.
• The filing was made on June 25, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a standard director stock option grant that is contingent on regulatory approval and does not immediately reflect company performance or strategic shifts.

Positives

• Grant of stock options to a director, indicating potential alignment of management interests with shareholders.
• The options are exercisable at a price of $10.14, suggesting a potential upside if the stock price increases.
• Vesting schedule over three years encourages long-term commitment from the director.

Negatives

• The grant is contingent on SEC approval, introducing uncertainty.
• The exercise price of $10.14 implies that the stock price needs to exceed this level for the options to be profitable.

Risks

• The primary risk is the potential disapproval by the SEC of the amended incentive compensation plan, which would invalidate the stock option grant.
• If the company's stock price does not appreciate above $10.14 by the expiration date of June 23, 2031, the options will expire worthless.
• The vesting schedule means the director's full benefit from the options is realized over several years, subject to continued service and company performance.

Future Outlook

The future outlook for the stock options is dependent on the SEC's approval of the amended incentive plan and the future performance of Daxor Corp's stock price relative to the $10.14 exercise price.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and healthcare sectors, aiming to incentivize leadership and align their financial interests with long-term shareholder value creation. However, the reliance on SEC approval for the incentive plan's amendment adds a layer of regulatory dependency not always present in such grants.

Corporate Governance

Related Party Transactions

• Grant of 2,500 stock options to Director Caleb DesRosiers with an exercise price of $10.14.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with potential stock appreciation, but the outcome is contingent on SEC approval and future stock performance.
• Employees: The amendment to the incentive plan, if approved, could pave the way for future grants to other employees.
• Management: Director DesRosiers has a vested interest in the company's stock performance over the next several years.

Next Steps

• Await SEC approval for the amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• Monitor Daxor Corp's stock performance relative to the $10.14 exercise price of the granted options.

Key Dates

Keywords

Daxor Corp, DXR, Form 4, Stock Options, Insider Trading, SEC Filing, Incentive Compensation Plan, Director Grant, Beneficial Ownership